Skip to main content
SINOTHERAPEUTICS INC. logo

SINOTHERAPEUTICS INC. — Investor Relations & Filings

Ticker · 688247 ISIN · CNE100005PL9 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 391 across all filing types
Latest filing 2025-05-19 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 688247

About SINOTHERAPEUTICS INC.

https://www.sinotph.com/en/

Sinotherapeutics Inc. is a pharmaceutical company specializing in the research, development, and commercialization of complex generic drugs and innovative drug delivery systems. The company focuses on high-barrier formulations, particularly oral solid dosage forms with modified-release or controlled-release profiles. Utilizing advanced technology platforms, Sinotherapeutics develops products designed to improve patient compliance and therapeutic outcomes. Its operations encompass the full lifecycle of drug development, from formulation design and clinical evaluation to large-scale manufacturing under global quality standards. The company maintains a robust pipeline targeting various therapeutic areas, including cardiovascular diseases, central nervous system disorders, and metabolic conditions. Sinotherapeutics aims to provide high-quality, affordable medications by leveraging its expertise in complex chemistry and pharmaceutical engineering.

Recent filings

Filing Released Lang Actions
国泰海通证券股份有限公司关于上海宣泰医药科技股份有限公司2024年度持续督导年度跟踪报告
Regulatory Filings
2025-05-19 Chinese
国泰海通证券股份有限公司关于上海宣泰医药科技股份有限公司2024年度持续督导工作现场检查报告
Regulatory Filings
2025-05-19 Chinese
自愿披露关于公司产品达格列净二甲双胍缓释片获得美国FDA批准文号的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding the voluntary disclosure of FDA tentative approval for a pharmaceutical product. It contains no financial statements, no detailed financial performance data, and no regulatory certifications or officer attestations. It is an announcement about a regulatory approval event related to the company's product, not a financial report or management discussion. The document length is short (1348 characters), and it is clearly an announcement of a significant corporate event. This fits best under the category of Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory announcements that do not fit other categories.
2025-05-12 Chinese
国泰海通证券股份有限公司关于上海宣泰医药科技股份有限公司部分董事、高级管理人员、财务负责人、核心技术人员变更的专项核查意见
Regulatory Filings
2025-05-05 Chinese
关于部分董事、高级管理人员、财务负责人、核心技术人员变更的公告
Board/Management Information Classification · 95% confidence The document is an announcement from Shanghai Xuantai Pharmaceutical Technology Co., Ltd. regarding changes in some directors, senior management personnel, financial officers, and core technical personnel. It details resignations, appointments, and nominations of various company officers and core technical staff, including their resumes and qualifications. The document is a formal disclosure of management and board changes, not a financial report, earnings release, or other types of filings. It does not contain financial data or results but focuses on personnel changes at the board and senior management level. Therefore, it fits the category of Board/Management Information (MANG). The document length and detail support this classification with high confidence.
2025-05-05 Chinese
关于召开2024年年度股东大会的通知
AGM Information Classification · 100% confidence The document is a detailed notice about the convening of the 2024 Annual General Meeting (AGM) of Shanghai Xuantai Pharmaceutical Technology Co., Ltd. It includes information about the meeting date, voting methods, agenda items including approval of the 2024 annual report, financial statements, profit distribution, election of directors, amendments to company articles, and other governance matters. The document also contains procedural details for shareholders to attend and vote, including proxy forms. The document is not the annual report itself but a formal announcement and notice for the AGM, including the agenda and voting instructions. It is consistent with the definition of AGM Information (AGM-R), which covers presentations and materials shared during the AGM or notices about the AGM. The document length is 3604 characters, which is relatively short and focused on the meeting notice rather than the full report or financial data. Therefore, the correct classification is AGM Information (AGM-R).
2025-05-05 Chinese

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.